Results 1 to 10 of about 18,095,855 (237)

Actinium-225 in Targeted Alpha Therapy

Journal of Medical Physics
The utilization of actinium-225 (225Ac) radionuclides in targeted alpha therapy for cancer was initially outlined in 1993. Over the past two decades, substantial research has been conducted, encompassing the establishment of 225Ac production methods ...
A. K. M. Rezaur Rahman, Mahathe Hasan Babu, Mustofa Khalid Ovi, Md. Mahiuddin Zilani, Israt Sultana Eithu, Amit Chakraborty   +5 more
doaj   +4 more sources

Quality control of actinium-225 and 225Ac-radiopharmaceuticals: Francium-221 to be or not to be?

EJNMMI Radiopharmacy and Chemistry
Background Actinium-225 radiopharmaceuticals have drawn great interest in cancer therapy due to their tumor-specific delivery of cytotoxic alpha-particles.
Miguel Toro-Gonzalez, Luke Wheeless, Vijai Kumar Reddy Tangadanchu, Cory Hawkins, Shannon Provo, William Smith, Michael Hommen, Dan DeVries, Jim Harvey, Tyler Drum, Diane S. Abou   +10 more
doaj   +4 more sources

Synthesis and Stability of Actinium-225 Endohedral Fullerenes, 225Ac@C60 [PDF]

ACS Omega, 2020
Abstract We report the first synthesis of 225Ac (t1/2 = 10 days) endohedral fullerenes,225Ac@C60. The 225Ac@C60 was produced with a 12 ± 2% efficiency by applying an electrical arc discharge between a source of α-particle emitter 225Ac (∼1 mCi, electroplated on a Pt disk) and a thin coat of “preformed” C60 on an Al disk (C60 thickness
Jofa Gideon Mwakisege, George Schweitzer, Saed Mirzadeh   +2 more
doaj   +3 more sources

Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review

Pharmaceutics, 2023
The actinium-225 (225Ac) radioisotope exhibits highly attractive nuclear properties for application in radionuclide therapy. However, the 225Ac radionuclide presents multiple daughter nuclides in its decay chain, which can escape the targeted site ...
Sipho Mdanda, Lindokuhle M. Ngema, Amanda Mdlophane, Mike M. Sathekge, Jan Rijn Zeevaart   +4 more
doaj   +4 more sources

Purification of Actinium-225 from Thorium via Selective Precipitation

Molecules
Numerous promising cancer treatments currently in clinical trials rely on the production and purification of actinium-225 (225Ac), an actinide with alpha emissions that can kill cancer cells via targeted alpha therapy.
Steven J. Schultz, Sara L. Adelman, Guy H. Dutech, Michael E. Fassbender, Christopher D. Henning, Brian N. Long, Kristen A. Pace, Stosh A. Kozimor, Veronika Mocko, Thomas E. Shaw   +9 more
doaj   +4 more sources

The determination of the radiochemical purity of Actinium-225 radiopharmaceuticals: a conundrum

EJNMMI Radiopharmacy and Chemistry, 2022
Janke Kleynhans, Adriano Duatti
doaj   +3 more sources

Actinium-225 production with an electron accelerator [PDF]

Journal of Applied Physics, 2021
There has been growing clinical evidence of the value of targeted alpha therapy for the treatment of several cancers. The work has been slowed by the lack of availability of the key alpha emitting isotopes, especially Ac-225. It can be produced by photonuclear reaction, Ra-226(γ,n)Ra-225.
Diamond, W. T., Ross, C. K.
openaire   +3 more sources

Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma

PLoS ONE, 2022
Hepatocellular carcinoma is the most common primary liver cancer and the fifth most frequently diagnosed cancer worldwide. Most patients with advanced disease are offered non-surgical palliative treatment options.
Yong Du, Angel Cortez, Anders Josefsson, Mohammadreza Zarisfi, Rebecca Krimins, Eleni Liapi, Jessie R. Nedrow   +6 more
doaj   +2 more sources

Gamma counting protocols for the accurate quantification of 225Ac and 213Bi without the need for a secular equilibrium between parent and gamma-emitting daughter

EJNMMI Radiopharmacy and Chemistry, 2022
Background Quantification of actinium-225 through gamma counter measurements, when there is no secular equilibrium between actinium-225 and its gamma emitting daughters bismuth-213 and/or francium-221, can provide valuable information regarding the ...
Dayana Castillo Seoane, Marijke De Saint-Hubert, Stephen Ahenkorah, Clarita Saldarriaga Vargas, Maarten Ooms, Lara Struelens, Michel Koole   +6 more
doaj   +1 more source

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model

Pharmaceuticals, 2022
In this study, we compared the tumor-targeting properties, therapeutic efficacy, and tolerability of the humanized anti-CAIX antibody (hG250) labeled with either the α-emitter actinium-225 (225Ac) or the β--emitter lutetium-177 (177Lu) in mice.
Robin I. J. Merkx, Mark Rijpkema, Gerben M. Franssen, Annemarie Kip, Bart Smeets, Alfred Morgenstern, Frank Bruchertseifer, Eddie Yan, Michael P. Wheatcroft, Egbert Oosterwijk, Peter F. A. Mulders, Sandra Heskamp   +11 more
doaj   +1 more source